THERAPEUTIC ADVANCES IN CHRONIC INFLAMMATORY DERMATOSES: A CURRENT ANALYSIS OF PSORIASIS AND ATOPIC DERMATITIS)

Abstract

This article aimed to analyze recent advances in the management of chronic inflammatory dermatoses, focusing on psoriasis and atopic dermatitis, highly prevalent immune-mediated diseases with substantial impact on quality of life. A literature review was conducted based on the selection of studies published between 2023 and 2025 in international scientific databases. After applying inclusion and exclusion criteria, ten studies met eligibility requirements and were included in the final analysis. The findings demonstrated that major therapeutic innovations involve the use of biologics targeting IL-17, IL-23, and IL-36 pathways for psoriasis, as well as anti-IL-4, IL-13, and IL-31 therapies and JAK inhibitors for atopic dermatitis. Emerging technologies such as advanced transdermal delivery systems and personalized medicine approaches were also identified as promising trends. The study concludes that, despite important scientific and clinical advancements, challenges persist regarding access, high treatment costs, and variability in therapeutic response, highlighting the need for continued research and strategies to enhance effectiveness and equity in the management of these conditions.